News

New X-Ray “Blueprint” of Pseudomonas Aeruginosa May Lead To New Cystic Fibrosis Therapies

Pseudomonas Aeruginosa is a complex, formidable bacterial infection that is notoriously difficult to treat, particularly in patients with lowered immune response and who have Cystic Fibrosis. While the bacteria’s mode of operation, which involves targeting and infecting damaged tissue, is relatively well understood, the method by which Pseudomonas Aeruginosa adapts to…

A Treatment Suitable for Half of Cystic Fibrosis Patients?

Positive test results for Vertex Pharmaceuticals’ newest Phase 3 clinical trials may expand the population of cystic fibrosis patients suitable to take a Vertex-produced drug from only 4% to nearly 50%. “It’s going to potentially allow us to get a medicine to 22,000 patients around the world with the…

KaloBios Continues KB001-A Trial For Pseudomonas Aeruginosa Infection in Cystic Fibrosis, Despite Dissolution of Sanofi Licensing Deal

San Francisco based KaloBios Pharmaceuticals, Inc. on Monday released an update on the status of its KB001-A monoclonal antibody development program, including news that multinational Sanofi Pasteur, which had been collaborating with Kalobios on the KB001-A R&D program, is pulling out of the partnership. KaloBios will regain all…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.